Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;40(8):1746-1747.
doi: 10.1002/mds.30272. Epub 2025 Jun 27.

Reply to: "Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS])"

Tanya Simuni  1 , Lana M Chahine  2 , Kathleen L Poston  3 , Catherine M Kopil  4 , Daniel Weintraub  5 , Billy Dunn  4 , Kenneth Marek  6
Affiliations

Reply to: "Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS])"

Tanya Simuni et al. Mov Disord. 2025 Aug.
No abstract available

PubMed Disclaimer

References

    1. Espay AJ, Cardoso F, Frucht SJ, Imarisio A, Halliday GM, Lees AJ. Refutation of the αSyn‐SAA‐based staging for Parkinson's progression (Neuronal α‐Synuclein Disease‐Integrated Staging System [NSD‐ISS]). Mov Disord 2025. - PubMed
    1. Simuni T, Gochanour C, Nair AR, et al. Neuronal alpha‐synuclein disease stage progression over 5 years. Mov Disord 2025. - PMC - PubMed
    1. Palmqvist S, Rossi M, Hall S, et al. Cognitive effects of Lewy bodypathology in clinically unimpaired individuals. Nat Med 2023;29:1971–1978. - PMC - PubMed
    1. Cummings JL, Teunissen CE, Fiske BK, et al. Biomarker‐guided decision making in clinical drug development for neurodegenerative disorders. Nat Rev Drug Discov 2025; Apr 4. 10.1038/s41573-025-01165-w. - DOI - PubMed

LinkOut - more resources